Intra-Cellular Therapies Executive Compensation (FY23)
ITCI · Executive and director compensation, fiscal 2022 to 2023
The paid brief on Intra-Cellular Therapies
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 14, 2026Latest filing (8-K): June 18, 2024
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
235 figures on this page: 226 cited to the filing that reported them, 9 calculated from figures it prints. See the citations
More on Intra-Cellular Therapies
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2022 to fiscal 2023
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Sharon Mates: $9,232,857 → $10,086,413 (9.2% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Intra-Cellular Therapies' chief executive and what were they paid?
Total compensation for Sharon Mates, Chairman and Chief Executive Officer, came to $10,086,413 in fiscal 2023. Mates' total moved 9.2% higher from the $9,232,857 reported for fiscal 2022.
What was Intra-Cellular Therapies' say-on-pay result?
The say-on-pay proposal drew 91.5% of votes cast for or against in favor at the meeting held June 14, 2024 for fiscal 2023.
Which companies are in Intra-Cellular Therapies' peer group?
Companies named in the disclosed peer group include ACADIA Pharmaceuticals Inc., Amicus Therapeutics, Inc., Apellis Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc. and Blueprint Medicines Corporation, among others.
What is Intra-Cellular Therapies' chief executive pay ratio?
For fiscal 2023, the company reported a chief executive pay ratio of 46:1, against median employee compensation of $217,585.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sharon Mates Chairman and Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Mark Neumann Executive Vice President, Chief Commercial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Michael Halstead President | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Suresh Durgam Executive Vice President, Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Lawrence Hineline Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Sharon Mates Chairman and Chief Executive Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Mark Neumann Executive Vice President, Chief Commercial Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Michael Halstead President | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Suresh Durgam Executive Vice President, Chief Medical Officer | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
Lawrence Hineline Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary | ◇ | ◇ | ◇ | — | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2023
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Lawrence J. Hineline | PSU | ◇ | — withheld | — withheld | — | ◇ | — | ◇ |
| Lawrence J. Hineline | PSU | ◇ | — withheld | ◇ | — | ◇ | — | ◇ |
| Mark Neumann | PSU | ◇ | — withheld | ◇ | — | ◇ | — | ◇ |
| Mark Neumann | PSU | ◇ | — withheld | — withheld | — | ◇ | — | ◇ |
| Michael I. Halstead | PSU | ◇ | — withheld | ◇ | — | ◇ | — | ◇ |
| Michael I. Halstead | PSU | ◇ | — withheld | — withheld | — | ◇ | — | ◇ |
| Sharon Mates | PSU | ◇ | — withheld | ◇ | — | ◇ | — | ◇ |
| Sharon Mates | PSU | ◇ | — withheld | — withheld | — | ◇ | — | ◇ |
| Suresh Durgam | PSU | ◇ | — withheld | — withheld | — | ◇ | — | ◇ |
| Suresh Durgam | PSU | ◇ | — withheld | ◇ | — | ◇ | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Mark Neumann | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Suresh Durgam | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Michael Halstead | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Lawrence Hineline | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Sharon Mates | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2023
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Robert L. Van Nostrand Lead independent director | ◇ | ◇ | ◇ | — | — | — | ◇ |
Joel S. Marcus | ◇ | ◇ | ◇ | — | — | — | ◇ |
Rory B. Riggs | ◇ | ◇ | ◇ | — | — | — | ◇ |
E. Rene Salas | ◇ | ◇ | ◇ | — | — | — | ◇ |
Sharon Mates served on the board in fiscal 2023 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Rsus/Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2023
- ACADIA Pharmaceuticals Inc. ACAD
- Amicus Therapeutics, Inc. FOLD
- Apellis Pharmaceuticals, Inc. APLS
- BioCryst Pharmaceuticals, Inc. BCRX
- Blueprint Medicines Corporation BPMC
- Exelixis, Inc. EXEL
- FibroGen, Inc. FGEN
- Halozyme Therapeutics, Inc. HALO
- Insmed Incorporated INSM
- Ionis Pharmaceuticals, Inc. IONS
- Neurocrine Biosciences, Inc. NBIX
- Pacira BioSciences, Inc. PCRX
- PTC Therapeutics, Inc. PTCT
- Sage Therapeutics, Inc. SAGE
- Sarepta Therapeutics, Inc. SRPT
- Supernus Pharmaceuticals, Inc. SUPN
- Ultragenyx Pharmaceutical Inc. RARE
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2023 | June 14, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 23, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 9, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 21, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 27, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | June 25, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | June 18, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | June 27, 2017 | = | ◇ | ◇ | ◇ |
| 2015 | June 14, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Intra-Cellular Therapies disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Intra-Cellular Therapies sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
235 figures on this page: 226 cited to the filing that reported them, 9 calculated from figures it prints.
226 cited to the filing
9 calculated from the filing
Documents cited
- 0001193125-24-163411Broker Non-Votes 88,688,988 3,237,807 4,299,788 0 4.
- 0001628280-24-018986Executive Officer and Director Compensation · Grants of Plan-Based Awards
- 0001193125-23-173823
- 0001193125-22-173000Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-21-196206
- 0001193125-20-154280Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-19-182626Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-18-199545Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-17-216728Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-16-622466Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Intra-Cellular Therapies executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/ITCI (accessed 2026).
Short form: data: Velarion
The paid brief for Intra-Cellular Therapies
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Intra-Cellular Therapies and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Intra-Cellular Therapies discloses
The companies named in ITCI's own disclosed peer group.
ACADIA Pharmaceuticals Inc.Amicus Therapeutics, Inc.Apellis Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc.Blueprint Medicines CorporationExelixis, Inc.FibroGen, Inc.Halozyme Therapeutics, Inc.Insmed IncorporatedIonis Pharmaceuticals, Inc.Neurocrine Biosciences, Inc.Pacira BioSciences, Inc.PTC Therapeutics, Inc.Sage Therapeutics, Inc.Sarepta Therapeutics, Inc.Supernus Pharmaceuticals, Inc.Ultragenyx Pharmaceutical Inc.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}